CBL-514

Caliway Biopharmaceuticals' novel drug CBL-514 demonstrated significant efficacy in Phase 2 trials for Dercum's disease, with 64.5% of painful lipomas showing ≥50% reduction or complete clearance.

Caliway Biopharmaceuticals has completed Taiwan's largest biotech IPO, raising $206 million and achieving a company valuation of nearly $3 billion.

Caliway Biopharmaceuticals' CBL-514 demonstrated significant efficacy in Phase 2b trial, with 54.2% of participants achieving at least 20% fat volume reduction in the abdominal area.

Caliway Biopharmaceuticals' CBL-514 has been granted Orphan Drug Designation by the EMA for the treatment of Dercum's disease, a rare and painful condition.

Caliway Biopharmaceuticals' CBL-514 receives Orphan Drug Designation from the EMA for Dercum's disease, marking it as the first drug with this designation.